Loading clinical trials...

A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes

A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 and Type 2 Diabetes

NCT01121276•Novo Nordisk A/S

Summary

This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 and type 2 diabetes.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Type 1 or type 2 diabetes mellitus for more than 12 months
•Treated with multiple daily insulin injections or continuous subcutaneous insulin infusion (CSII) for 12 months or longer for subjects with type 1 diabetes and for 3 months or longer for subjects with type 2 diabetes
•Body Mass Index (BMI) between 18.0-32.0 kg/m2 (both inclusive)

Exclusion Criteria

•Surgery or trauma with significant blood loss (more than 500 mL) within the last 3 months prior to trial start
•Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)
•Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period

Locations (1)

Novo Nordisk Investigational Site

Chula Vista, California, United States

Key Dates

Start Date

April 1, 2010

Primary Completion Date

September 1, 2010

Completion Date

September 1, 2010

Last Updated

January 18, 2017

Enrollment

ACTUAL participants

Conditions

DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Interventions

Faster-acting insulin aspart

DRUG

insulin aspart

DRUG

Faster-acting insulin aspart

DRUG

Faster-acting insulin aspart

DRUG

Faster-acting insulin aspart

DRUG

Genetic Studies of Insulin and Diabetes

NCT00001987

Diabetes MellitusSevere Insulin Resistance

View study

RECRUITINGNA

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 18, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes

Inclusion Criteria

Exclusion Criteria

Genetic Studies of Insulin and Diabetes

Feasibility of a Tailored Online Self-compassion Intervention

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes